Introduction
============

Parkinson's disease (PD) is the second most common chronic neurodegenerative disease in the elderly population. The motor symptoms that characterize PD are bradykinesia, tremor, rigidity, and postural instability, together with non-motor symptoms such as depression, anxiety, sleep disorders and cognitive dysfunction. These symptoms lead to severe impairment of the quality of life for the PD patient ([@B41]). Pathological analyses of *post-mortem* brains have shown Lewy bodies, which are abnormal protein aggregates found within nerve cells, and a progressive loss of *substantia nigra* dopamine neurons ([@B55]). Among the molecular mechanisms suggested to cause PD are cellular oxidative stress and autophagy. Pesticide exposure, use of well water, heavy metal exposure, and industrialization are some of the environmental factors that contribute to the development of PD ([@B147],[@B148]).

Over recent years, extensive genetic screening of PD families has aimed at identifying mutations associated with the disease that would give a deeper insight into the molecular mechanisms underlying the PD pathology. Genetic studies identified several genomic risk *loci* associated with familial PD, such as *PARK1-15* and other related genes ([@B88]; [@B18]). Additionally, other genes, including *LRRK2*, *SNCA*, *MAPT*, and *GBA*, have been associated with sporadic PD ([@B23]). Even though there is evidence that PD can be caused sporadically by familial genetic mutations (causal mutations), such as in *alpha-synuclein* (*SNCA*) or *Parkin*, it is more likely that in most patients the disease develops as a consequence of the combination of mutations in multiple PD-associated genes and environmental risk factors.

In addition to the genetic component involved in the development of many disorders (acquired mutations in one gene or a group of genes), epigenetic mechanisms have been found to contribute significantly to their development. Epigenetic factors are chemical modifications of chromatin or its regulatory proteins that do not change the underlying genomic sequence. These modifications can modulate gene expression, allowing differentiation into different cellular phenotypes by driving tissue-specific expression patterns. These changes include DNA methylation, post-translational modifications of histones, chromatin remodeling, as well as small and long non-coding RNAs ([@B135]).

Epigenetic regulation of biological processes is known to be essential during embryonic development, early brain programming, neurogenesis and brain plasticity ([@B153]). Therefore, it is not surprising that epigenetic deregulation can be critical for the onset of various neurodegenerative diseases, such as PD ([@B2]). Previously, a comprehensive genomic study identified several PD risk *loci* in cerebellum and frontal cortex of PD brains, including *PARK16*, *GPNMB*, and *STX1B* genes, that were associated with differential DNA methylation at proximal CpG sites ([@B56]).

Importantly, as there is currently no animal model that mimics PD; human brain is still the model used to study epigenetic changes. However, as PD brain tissue is predominantly analyzed *post-mortem*, this data cannot provide information about disease-progressive alterations, the extent of variations induced by previous therapeutic treatments and the occurrence of potential PD biomarkers. Access to brain samples for research is limited, so the focus has been on finding a more easily accessible tissue, such as peripheral blood, as a surrogate for brain tissue. For this purpose, a genome-wide study examined DNA methylation changes in PD patients by collecting fresh *post-mortem* brain and blood samples from PD patients and age-matched healthy subjects ([@B87]). This comparison revealed that both tissues exhibited highly similar global DNA methylation patterns. Accordingly, [@B87] identified groups of genes with either increased or decreased DNA methylation in both PD brain and blood samples. Importantly, analysis of DNA methylation profiles of blood clearly distinguishes PD patients from healthy subjects or subjects with other disorders. These results suggest that, firstly, peripheral blood may be a valid surrogate for brain tissue samples, and secondly, epigenetic changes could potentially serve as biomarkers for the diagnosis of PD. Early biomarkers could improve the prognosis of PD by facilitating the initiation of rational treatment before significant neurological damage takes place. Here, we discuss the current evidence for DNA methylation changes in PD, including the involvement of nutrition and environmental factors.

The Role of DNA Methylation in Disease and Aging
================================================

DNA methylation is the most studied epigenetic modification, one that has been investigated in almost all pathologies. In mammals, DNA methylation takes place predominantly in the context of CpG dinucleotides ([@B37]). While overall the genome is widely depleted of CpGs, CpG islands are regions of high CpG content ([@B129]; [@B150]). CpG islands are characteristic for more than 60% of all promoters of protein-coding genes. Whereas on a genome-wide level up to 70--80% of all CpG sites are methylated, CpG islands are mostly devoid of DNA methylation ([@B8]; [@B36]). Adjacent to a CpG island, 2 kilo base pairs (kb) up- and down-stream, are its so-called CpG shores ([@B57]). The presence of DNA methylation, at least at gene promoters and regions of repetitive sequences, is linked to chromatin silencing ([@B54]; [@B116]). Two principal mechanisms, which are not mutually exclusive, are thought to explain the repressive effect of DNA methylation on gene repression ([@B9]; [@B70]). First: DNA methylation interferes with the recognition of transcription factor (TF) binding sites and thereby impairs gene activation ([@B35]). Second: DNA methylation is recognized by specific Methyl-CpG binding proteins, such as MeCP2, that recruit co-repressor protein complexes and thereby mediate silencing ([@B96]). Aberrant methylation patterns at CpG islands and shores have been linked to human disease, including multiple cancers ([@B100]; [@B57]; [@B6]; [@B84]).

In developing embryos and germ cells, DNA methylation patterns are first established by *de novo* DNA methyltransferases (DNMTs), DNMT3A and DNMT3B. After this, DNA methylation is maintained during DNA replication by DNMT1, which localizes to the replication fork during S-phase where it binds to hemimethylated CpGs ([@B61]; [@B63]). In 2009, ten-eleven translocation (TET) enzymes were identified that can reverse DNA methylation, by oxidization of 5-methyl cytosine (5mC) to 5-hydroxymethyl cytosine (5hmC) ([@B128]; [@B103]). 5hmC can be lost passively by dilution during replication or be actively removed by subsequent oxidative reactions catalyzed by TET proteins that result in the formation of 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) as intermediates ([@B58]). Finally, the thymine DNA glycosylase (TDG)-mediated base excision repair (BER) replaces the methylated site by an unmodified cytosine ([@B51]; [@B71]).

Importantly, it appears that the 5hmC modification is not only an intermediate of 5mC demethylation, but has been considered to be an epigenetic mark in itself. Although the exact role of 5hmC is still being studied intensively, it seems to have a distinct function from that of 5mC. Particularly in neuronal cells, DNA hydroxymethylation was found to be enriched in gene bodies of actively transcribed genes ([@B91]; [@B49]). Given the relative abundance of DNA hydroxymethylation in the brain and its apparent role in normal brain maturation and memory formation ([@B127]; [@B65]; [@B79]; [@B69]), it has been implicated in the onset and progression of several neurodegenerative disorders ([@B138]; [@B139]; [@B22]; [@B24]). Although not as widespread as 5mC and 5hmC, there is emerging evidence that cytosine methylation also exists outside of the sequence context of CpG sites (non-CpG methylation: CpA, CpT, and CpC) and appears to be most common in embryonic stem cells ([@B80]) and adult brain tissue ([@B136]; [@B48]). Non-CpG methylation occurs postnatally during the primary phase of neuronal maturation and may play a role in transcriptional repression ([@B79]; [@B48]). However, as it is technically challenging to target this modification *in vivo* without altering CpG methylation in the process, extensive research is still required to elucidate the distinct biological function of non-CpG methylation.

Genetically, aging is characterized by distinct alterations that take place at the chromatin level. These include telomere shortening, increased genome instability and changes of epigenetic signatures, such as DNA methylation patterns ([@B82]). Age-related remodeling of DNA methylation comprises events of both hypo- and hypermethylation ([@B83]; [@B64]). DNA hypomethylation happens globally at CpG sites outside of CpG islands ([@B19]; [@B52]; [@B29]), while DNA hypermethylation affects mostly CpG islands in promoters of genes, which are frequently involved in development and differentiation ([@B19]; [@B108]). Therefore, over time the accumulation of epimutations, which are heritable changes of gene activity mediated by epigenetic alterations, are believed to contribute to genomic instability just as genetic mutations do.

Interestingly, the methylation states at specific CpG *loci* can be consulted as epigenetic biomarkers to reliably predict the human chronological age ([@B53]; [@B143]). Moreover, twin studies determined that in each human, the age-dependent aggregation of distinct epigenetic changes, termed 'epigenetic drift,' is thought to be influenced predominantly by environmental factors ([@B40]; [@B130]). The individual differences in exposure to these factors are suspected to contribute to variation in disease susceptibility, onset, progression, etiopathology, treatment response and disease outcome. Taken together, changes in DNA methylation patterns and their effects on chromatin and gene expression appear to add increasingly to our understanding of age-related diseases, including PD. In the following, we will summarize and discuss the current evidence of DNA methylation changes at candidate genes that could be related to the development of PD.

DNA Methylation and PD: Analysis of the *SNCA* Gene
===================================================

The *SNCA*p.Ala53Thr mutation, described in 1997, was the first genetic cause of PD identified ([@B106]). This missense mutation provided the first link between *SNCA* and familial PD after its identification in a family from Southern Italy. The respective gene product, the SNCA protein, was discovered almost simultaneously ([@B123]). At the molecular level, SNCA aggregation contributes majorly to the formation of Lewy bodies, a hallmark of PD pathology. In addition to genetic mutations, also *SNCA locus* amplifications (duplications, triplications) have been found as a cause of familial PD ([@B118]; [@B17]). *SNC*A point mutations, as well as gene multiplications and overexpression, are all thought to play a causal role in the formation of Lewy bodies ([@B97]; [@B88]). That *SNCA* gene dosage is critical for the development of PD, was further supported by mouse models with neuronal expression of wild-type *SNCA* ([@B88]; [@B59]). These transgenic mice revealed PD-like loss of dopaminergic neurons, protein aggregate formation, and motor impairments.

As gene dosage can be changed not only by gene amplification, but also by gene regulation, DNA methylation was considered as a potential mechanism that could be involved in the deregulation of *SNCA* in the case of PD. Accordingly, sequence analysis of the promoter region of the *SNCA* gene led to the identification of two CpG islands ([@B90]). The first, CpG-1 is located in the first exon but does not overlap with the coding region of *SNCA*, and the second, CpG-2 is located in the first intron. In luciferase reporter assays the promoter activity of sequences containing CpG-2 was indeed strongly reduced by *in vitro* DNA methylation prior to cell transfection ([@B62]; [@B90]). Furthermore, treatment of SK-N-SH cells with a DNA methylation inhibitor resulted in a reduction of CpG-2 methylation and a significant increase of *SNCA* mRNA and protein levels ([@B62]). These data supported the idea that DNA methylation at least at the intronic CpG-2 island could control *SNCA* gene activity. In fact, several studies analyzing the DNA methylation levels in samples of PD patients compared to controls confirmed a hypomethylation of intron 1 that coincides with the second *SNCA* CpG island. Using brain samples a significant demethylation of intron 1 was reported in the *substantia nigra pars compacta* (SnPC) of PD patients which could explain increased *SNCA* expression ([@B62]; [@B90]). Taking into account the observation that DNA methylation patterns between blood and brain tissue show a strong correlation ([@B87]), more recent studies analyzed peripheral blood samples of PD subjects instead of or in addition to *post-mortem* brain tissue. In agreement with the assumption that DNA methylation profiles in the brain could be potentially mirrored in blood cells, a recent study found *SNCA* promoter hypomethylation in both *post-mortem* cortex and peripheral blood samples ([@B105]). Another study reported hypomethylation of *SNCA* intron 1 in peripheral blood mononuclear cells of 100 sporadic PD subjects ([@B1]). In 2015, the largest study carried out to date analyzing 490 peripheral blood samples of patients with sporadic PD, also revealed hypomethylation of *SNCA* intron 1. In contrast, *SNCA* methylation was found to be increased in PD patients who received higher L-dopa dosage. Accordingly, L-dopa led to a specific increment of DNA methylation of *SNCA* intron 1 in mononuclear cell cultures. Interestingly, the detection of DNMT1 in *post-mortem* brain tissue of PD patients and in *SNCA* transgenic mice uncovered that the amount of enzyme was strongly reduced in the nuclear fraction of neuronal cells ([@B34]). Thus, sequestration of DNMT1 in the cytosol could explain the global, as well as the *SNCA* gene-specific, PD-dependent DNA hypomethylation, mechanistically.

In recent years, meta-analyses of genome-wide association studies (GWAS) on single nucleotide polymorphism (SNP) data of large PD case-control cohorts were conducted ([@B95], [@B94]; [@B114]). These studies identified risk *loci* in both genes, previously not linked to PD pathology, and known key players, such as *SNCA*. Thereby, obtained results substantiated that there is a major genetic component contributing to the susceptibility to PD. But additionally, inter-individual genetic variants can frequently be associated with DNA methylation differences at distinct CpG sites and are defined in statistical analyses as methylation quantitative trait *loci* (mQTLs). Two recent studies investigated the relationship between genetic variation and CpG methylation in the human brain ([@B43]; [@B157]). In case of the *SNCA* gene, three independent studies noted that the genotype SNP rs3756063 showed a significant correlation with the DNA methylation state of *SNCA* intron 1 both in brain and blood PD samples ([@B105]; [@B112]; [@B142]). However, it should be noted that an association between rs3756063 and the *SNCA* mRNA expression could not be found ([@B105]; [@B142]). Furthermore, another association could be established between the *SNCA* DNA methylation levels and the Rep1 polymorphism ([@B1]). In contrast to rs3756063, Rep1 is a complex microsatellite repeat polymorphism located approximately 10 kb upstream of the *SNCA* transcription start site (**Figure [1](#F1){ref-type="fig"}**). Its longest 263 bp allele has previously been associated with sporadic PD ([@B85]). In agreement with an elevated PD risk, genotypes carrying the 263 bp allele showed the strongest *SNCA* intron 1 hypomethylation ([@B1]). Experiments in transgenic mice suggested a *cis*-regulatory effect of the Rep1-length regulating *SNCA* transcription, whereby homozygosity of the expanded 263 bp allele correlated with the highest gene expression ([@B27]). Controversially, recent data obtained by the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 technique, to edit the genome Rep1 *locus* in human embryonic stem cell-derived neurons, contradict the enhancer function of the repeat sequence and do not detect a correlation between *SNCA* expression and Rep1-length ([@B121]). Likewise, the interdependency between DNA methylation alterations in the *SNCA locus* and genetic variants, is not understood mechanistically, neither in case of Rep1 nor rs3756063. Genetic variation does not only impact DNA methylation, but also dictates differences in binding of TFs in individuals on a genome-wide level ([@B67]). Therefore, it will be a great challenge to unravel the molecular mechanisms behind these associations, as they are expected to be connected with each other in a complicated network.

![DNA methylation patterns in PD at the promoter region of the *SNCA* gene. **(Upper)** The promoter region and 5′ end of the *SNCA* gene containing the core promoter and the two first exons of *SNCA* (Exon 1 and Exon 2) are depicted. Exon 2 contains the ATG start codon of the open reading frame (ORF). Upstream of the promoter the location of the polymorphic microsatellite sequence Rep1 is shown. Below the scheme of the *SNCA* gene the CpG-rich region is depicted as an CpG island (CGI). Positions of regulatory sequences (promoter and CGIs), as well as exons and introns are given at the top in reference to the ATG start codon. **(Lower)** Regulatory sequences and intronic regions analyzed in various studies (see text for more detail) are depicted as boxes. The references are given on the left, and the DNA methylation status and source of PD samples on the right.](fnmol-10-00225-g001){#F1}

Although the studies cited above suggest DNA hypomethylation of the *SNCA* promoter region in PD patients, discrepancies with other findings exist. For example, one study revealed variations of DNA methylation levels at the *SNCA* gene in different brain regions. Both hypomethylation, as well as hypermethylation, were detected in various Lewy body disease/PD stages in both the promoter region and intron 1 ([@B30]). Another recent study found no intron 1 hypomethylation of *SNCA* in a limited number of PD patients ([@B47]). Moreover, the analysis of blood samples from 43 PD subjects provided no evidence for DNA methylation changes within the *SNCA* promoter region ([@B110]), just as another study comprising blood leukocyte samples of 50 PD patients ([@B122]). However, it should be noted, that in the latter two studies ([@B110]; [@B122]) 10 times less subjects participated compared to the analysis of [@B112] that detected differential DNA methylation at the *SNCA* gene.

In light of the inconsistencies concerning the relevance of DNA hypomethylation at the *SNCA* intron 1 in association with PD, additional studies will be needed to resolve these doubts. Also, even if *SNCA* intron 1 hypomethylation can be consistently confirmed in PD, similar DNA patterns were also found in both Dementia with Lewy Bodies (DLB) ([@B42]) and AD ([@B154]). Therefore, it is conceivable that this DNA methylation change would not serve as a specific biomarker for PD, but a more general one for all Lewy body pathologies.

DNA Methylation Patterns at PD-Associated Genes
===============================================

In the following section, we will give an overview of what is known so far about the epigenetic signatures of DNA methylation at genes that were found to be associated with the development of PD (compare **Table [1](#T1){ref-type="table"}**).

###### 

DNA methylation status of PD associated genes.

  Gene                   Alias                                                                                                                                                                                                                                                                                Location              DNA methylation                    Reference
  ---------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------- ---------------------------------- --------------------------------------------------------------------------------------------------------------------------
  *PAD2*                 Peptidyl arginine deiminase 2                                                                                                                                                                                                                                                        1p36.13               No difference                      [@B89]
  *ATP13A2*              *PARK9*                                                                                                                                                                                                                                                                              1p36.13               No difference                      [@B5]
  *DJ-1*                 *PARK7*                                                                                                                                                                                                                                                                              1p36.23               No methylation                     [@B131]
  *NPAS2*                Neuronal PAS2                                                                                                                                                                                                                                                                        2q11.2                Hypomethylation                    [@B78]
  *UCHL1*                Ubiquitin C-terminal hydrolase L1                                                                                                                                                                                                                                                    4p13                  No difference                      [@B4]
  *PGC1-*α               Peroxisome proliferator-activated receptor gamma coactivator 1-alpha                                                                                                                                                                                                                 4p15.2                Hypermethylation                   [@B126]
  *TNF-*α                Tumor necrosis factor-alpha                                                                                                                                                                                                                                                          6p21.33               No difference                      [@B104]
  *PARK2*                Parkinson juvenile disease protein 2, *Parkin*                                                                                                                                                                                                                                       6q26                  No difference                      [@B14]
                                                                                                                                                                                                                                                                                                                                    No difference                      [@B32]
  *CYP2E1*               Cytochrome P450-J                                                                                                                                                                                                                                                                    10q26.3               Hypomethylation                    [@B68]
  *NOS2*                 Nitric oxide synthase 2                                                                                                                                                                                                                                                              17q11.2               Hypomethylation                    [@B113]
  *MAPT*                 Microtubule associated protein Tau                                                                                                                                                                                                                                                   17q21.31              Differential methylation           [@B26]
  *FANCC/TNKS2*          Fanconi anemia group C protein/tankyrase 2                                                                                                                                                                                                                                           9q22.32/10q23.32      Differential methylation           [@B93]
  *PARK16/GPNMB/STX1B*   *PARK16/*glycoprotein Nmb*/*syntaxin 1B                                                                                                                                                                                                                                              1q32/7p15.3/16p11.2   Differential methylation           International Parkinson's Disease Genomics Consortium \[IPDGC\], and Wellcome Trust Case Control Consortium 2 \[WTCCC2\]
  Genome-wide            Top 30 differentially methylated genes: *KCTD5, VAV2, MOG, TRI M10, HLA-DQA1, ARHGEF10, GFPT 2, HLA-DRB5, TMEM9, MRI 1, MAPT, HLA-DRB6, LASS3, GSTTP 2, GSTTP. DNAJA3, JAKMIP 3, FRK, LRR C27, DMBX1, LGALS7, FOXK1, APBA1, MAGI2, SLC25A24, GSTT 1, MYOM2, MIR886, TUBA3E, TMCO3*                         Hypermethylation Hypomethylation   [@B87]

From left to right: Listed are genes, gene aliases, genomic locations (according to the latest GRCh38/hg38 assembly of the human genome available at the UCSC genome browser), DNA methylation status in PD and references

.

Due to its relation to *SNCA* and its abundance in neurofibrillary lesions of patients with AD, the *beta-synuclein* (*SNCB*) gene has also been considered as a possible player in PD. Interestingly, SNCB inhibits the generation of SNCA fibril aggregation *in vitro* ([@B102]) and therefore, may play a neuroprotective role ([@B137]). Furthermore, *SNCB* and *SNCA* have similar expression levels in nervous system tissue samples ([@B86]). Moreover, SNCA and SNCB associate *in vitro* whereby SNCB may protect SNCA from aging-related protein damage ([@B137]). However, to date, the specific role SNCB plays in PD has not been elucidated. A DNA methylation study carried out in PD samples to examine the *SNCB* gene found its promoter to be unmethylated in *post-mortem* brain from PD and PD-Dementia samples. Additionally, bisulfite sequencing of the *SNCB* promoter in four pure diffuse Lewy body pathology cases did not reveal methylated cytosines along the CpG island ([@B7]).

Post-translational citrullination (deimination) is mediated by peptidyl arginine aminases (PADs) and has been implicated as an unusual pathological trait in neurodegeneration and inflammatory responses in multiple sclerosis, AD and prion diseases ([@B60]). Alterations in the expression of these proteins have also been seen in *post-mortem* samples taken from different brain areas of PD subjects ([@B98]). In thymus samples from multiple sclerosis patients, the promoter of *PAD2* (peptidyl arginine deaminase type II) was reported to be hypomethylated ([@B120]). In contrast, white matter from PD, AD, or Huntington disease patients showed that *PAD2* was not hypomethylated ([@B89]). DNA methylation analysis of the tumor necrosis factor alpha (TNF-alpha) gene, another PD-associated gene, showed a significantly lower methylation level comparing DNA from the SnPC to DNA from brain cortex. However, this difference could not be linked to PD as it was observed in both PD subjects and controls ([@B104]). In another study, the *UCHL1* promoter from *post-mortem* frontal cortex samples was analyzed, and no differences in the percentage of CpG methylation between PD cases and controls were found ([@B4]).

Behrens et al. analyzed the *ATP13A2* promoter region from four PD subjects with Kufor-Rakeb syndrome, a rare Type 9 juvenile PD that is linked to a mutation in the *ATP13A2* gene ([@B5]). No significant correlation between DNA methylation changes of the hypomethylated promoter and Kufor-Rakeb syndrome juvenile PD progression was found. Another study considered the known association of *Parkin* (*PARK2*) gene mutations with autosomal recessive juvenile PD. Samples from 17 PD subjects with heterozygous *Parkin* mutations, as well as 17 PD subjects without *Parkin* mutations, were compared to samples from 10 normal subjects. No significant differences in DNA methylation at CpG sites among these three groups were found, suggesting that a DNA methylation-related mechanism involving the *Parkin* gene was unlikely to play a role in the pathogenesis and development of this type of PD ([@B14]). A recent study compared the DNA methylation status of the *PARK2* promoter region in 5 *post-mortem* brain samples taken from *substantia nigra*, cerebellum, and occipital cortex ([@B32]). In agreement, with previous results ([@B14]) no differential DNA methylation of *PARK2* was seen ([@B32]).

The expression of clock genes, which are components of the circadian clock, is altered in leukocytes from patients with PD ([@B15]). With this in mind, a study was recently carried out in which DNA methylation status of the clock genes *PER1*, *PER2*, *CRY1*, *CRY2*, *Clock*, *NPAS2*, and *BMAL1* was measured in genomic DNA isolated from blood samples of 206 PD subjects. DNA methylation was detectable in *CRY1* and *NPAS2* promoters whereas the remaining gene promoters analyzed were devoid of DNA methylation. Interestingly, DNA methylation frequency of the *NPAS2* promoter was significantly decreased in PD patients, suggesting that its promoter DNA methylation may contribute to the expression of clock genes in PD ([@B78]). This finding could be relevant, as sleep disturbance is a commonly reported early symptom of PD ([@B13]).

Another gene of interest for the analysis of epigenetic changes is the microtubule-associated protein tau (*MAPT*) gene, as a genetic association with PD has been noted in GWAS ([@B117]). When 28 *post-mortem* brain and 358 blood leukocyte samples were analyzed, higher DNA methylation in MAPT was detected in H1 haplotype versus H2 ([@B26]). Notably, in previous studies the presence of the H1 haplotype was associated significantly with PD ([@B75]; [@B156]; [@B109]). Additionally, DNA hypermethylation of the MAPT gene was observed in the cerebellum, but not in putamen from PD subjects where the MAPT gene was hypomethylated as compared with controls ([@B26]).

DNA hypermethylation of the peroxisome proliferator-activated receptor gamma coactivator-1 α (PGC-1α) promoter was reported in a sample of sporadic PD *substantia nigra* samples compared to 10 age-matched controls ([@B126]). Recently, *PARK7* (*DJ-1*) DNA methylation was analyzed in peripheral blood leukocytes in PD subjects and controls. In contrast to the hypermethylated PGC-1α promoter ([@B126]), they found the CpG-1 and CpG-2 islands of *PARK7* to be unmethylated in both PD and the negative control group ([@B131]).

To detect further PD associated DNA methylation variations, an epigenome-wide association study was done to analyze DNA methylation patterns in putamen samples from *post-mortem* brain tissue of six PD patients. DNA methylation levels were quantitatively determined at 27,500 CpG sites representing 14,495 genes. This analysis revealed decreased DNA methylation at the cytochrome P450 2E1 (*CYP2E1*) gene, together with increased expression of the respective *CYP2E1* messenger RNA, suggesting that this cytochrome gene may contribute to PD susceptibility. In another epigenome-wide association study, conducted to reveal prioritized genes and pathways with statistically significant DNA methylation changes in PD, followed by a subsequent replication analysis of top-ranked CpG sites, single CpG sites of *FANCC* and *TNKS2* showed significant differential methylation between PD cases and controls ([@B93]). In total, 20 unique genes were identified with a sizable difference in DNA methylation.

Despite the lack of conclusive evidence for the involvement of DNA methylation in the epigenetic regulation of many PD-associated genes, the search for other PD-associated genes and their DNA methylation status is ongoing. Undoubtedly, the significance and consistency of results of genomic DNA methylation in promoter regions of blood samples in comparison with brain samples need to be tested further. Unfortunately, findings from studies searching for PD-specific DNA methylation signatures at the *SNCA* gene and other PD-associated genes are still inconsistent concerning the clinical significance and specificity of DNA methylation changes in PD. Most importantly, experimental evidence that directly links DNA methylation changes in PD to the deregulation of these genes is still missing. Thus, the importance of differential DNA methylation for molecular mechanisms contributing to the development of PD remains to be investigated in future studies.

Nutritional Factors and their Implications for PD
=================================================

DNA Methylation and Folate Deficiency
-------------------------------------

In recent years, several studies have attempted to pinpoint an interrelation between DNA methylation and folate. However, a significant association between DNA methylation levels and folate status could not always be consistently replicated ([@B141]; [@B140]; [@B124]; [@B134]; [@B115]). Apart from folate, many other nutrients are known to play key roles in one-carbon metabolism and DNA methylation. More accurate studies that analyze the contribution of other nutrients involved in DNA methylation and gene-diet interactions for PD risk are necessary.

The extent of DNA methylation in the cell is directly associated with the physiological level of SAM, the major methyl donor for DNA methylation, and SAH, the demethylation product of SAM and an inhibitor of DNA methyltransferases. The ratio SAM/SAH is interpreted as the methylation potential and is determined by the homocysteine concentration. The latter is considered a biomarker of folate deficiency, as it is dependent on 5-methyl tetrahydrofolate (THF) availability in the one-carbon metabolism. The physiologic levels of homocysteine and subsequent methylation potential are determined primarily by the dietary intakes of methionine, folate, B12 vitamin and other nutrients.

Importantly, elevated levels of homocysteine may have a toxic effect on dopaminergic neurons ([@B31]; [@B45]). Consistently, higher homocysteine concentrations have been reported in PD patients compared to controls. Moreover, serum homocysteine levels predict the SAM/SAH ratio in plasma, and the concentration of SAH shows a significant correlation with markers of neurodegeneration (Amyloid Precursor Protein and SNCA). This evidence supports the use of total homocysteine and SAM/SAH ratio as biomarkers of the DNA methylation potential in patients with PD ([@B99]). However, we still lack information about the direct effect of nutrient intake on genomic DNA methylation, especially regarding the combinatorial effects of nutrients with other factors, such as gene polymorphisms and/or therapeutic drugs.

One-Carbon Metabolism and Polymorphisms
---------------------------------------

The presence of SNPs in genes encoding enzymes and transporters involved in the folate metabolism, impair methyl group bioavailability and have been associated with altered blood concentrations of biochemical markers, including folate, vitamin B12 and homocysteine ([@B50]; [@B132]; [@B77]). Importantly, some SNPs led to changes of homocysteine levels and were associated with differences in global DNA methylation levels ([@B145]). Other SNPs have also been associated with diseases, such as neural tube defects ([@B16]; [@B39]; [@B101]; [@B81]) and different types of cancers ([@B28]; [@B21]; [@B44]; [@B76]; [@B92]; [@B144]).

The C677T variant (rs1801133), in the gene encoding the enzyme methylene-tetrahydrofolate reductase (MTHFR), is one of the most-studied SNPs occurring in components of the one-carbon metabolism. The base C677T substitution results in an amino acid change in the catalytic domain of the enzyme. This variation leads to a reduced protein stability and a 30% and 65% reduction of enzymatic activity in heterozygotes (CT) and homozygotes (TT), respectively ([@B111]). Notably, the C677T variant has been previously reported to be associated with PD susceptibility ([@B31]; [@B151]). A recent meta-analysis including data from fifteen studies (comprising 2690 PD cases and 8465 controls) did not find an appreciable difference in the general allelic frequency distribution of C677T between PD cases and controls ([@B158]). However, in separate analyses that were stratified for ethnicity, a clear association was detected in Europeans (OR = 1.17), but not in Asians. Interestingly, this appears to be in line with the observation that the allelic frequency of the MTHFR C677T variant differs considerably between ethnic groups ([@B146]; [@B46]). Furthermore, this study confirmed that the T allele is an independent risk factor for increased homocysteine levels in PD patients ([@B158]). In contrast, the results of a cohort study analyzing Chinese patients suggested that the A-T haplotype of A1298C, another common MTHFR variant, and C677T decreases the PD susceptibility ([@B155]). The inconsistent findings for the association between C677T and PD may be explained by different genetic backgrounds, environmental factors or DNA methylation modulation.

Other Nutritional/Environmental Factors and DNA Methylation
===========================================================

Coffee Drinking
---------------

The risk for PD is ∼25% lower for coffee drinkers with a linear dose-response effect ([@B25]; [@B33]). Caffeine is thought to act as an adenosine receptor antagonist, and to reduce inflammation and lipid-mediated oxidative stress ([@B38]; [@B72]).

Little is known whether DNA methylation changes can arise in response to distinct coffee consumption patterns. A recent study using blood tissue data of patients without PD found the methylation status of CpG sites located near genes previously linked to some familial forms of PD (*GBA*, *PARK2/Parkin*, and *PINK1*) associated with coffee consumption ([@B20]). However, whether distinct DNA methylation levels at these CpG sites in coffee-drinkers are indeed protective against PD, remains to be further investigated.

Manganese
---------

Manganese (Mn) is an essential element, but some industrial activities can result in exposure to high occupational and environmental Mn levels ([@B12], [@B11]). In the environment, Mn in drinking-water and foods may also contribute to toxic effects ([@B3]).

Exposure to excessive amounts of Mn may lead to adverse health outcomes, and evidence suggests that DNA methylation changes induced by Mn may play a relevant role. Regarding PD risk, gene activity of *PARK2* and *PINK1* was altered via DNA hypermethylation in dopaminergic human neuroblastoma SH-SY5Y cells upon Mn exposure ([@B133]). Furthermore, mice exposed to MnCl~2~ showed DNA hypo- and hypermethylation of different *loci* in *substantia nigra* ([@B152]). In human, the effects of Mn on parkinsonism via DNA methylation changes was assessed in welders' blood samples. Interestingly, subjects recently exposed to welding fume had lower *NOS2* gene DNA methylation than subjects retired from welding worksites. Also, an inverse association between duration of welding fume exposure and DNA methylation of a *NOS2* CpG site was observed ([@B113]).

Endocrine Disruptors and Pesticides
-----------------------------------

It is proposed that other factors, such as endocrine disruptors or pesticide exposure, may play a role in modulating DNA methylation, although the evidence from studies with PD patients or animal models is still limited. Results from experimental, clinical, and epidemiological studies implicate exposure to endocrine disruptors with processes related to neurodegenerative diseases ([@B66]; [@B107]). Among these compounds, Bisphenol-A has been linked to lower levels of DNA methylation in cerebral cortex and hippocampus in mice ([@B73]). Several studies have shown an association with frequent pesticide exposure in men and late-onset PD ([@B33]). Recent findings show that organochlorines exposure of hippocampal-primary cultures causes global hypomethylation of DNA ([@B149]).

Although research suggests that these and other environmental exposures can modify epigenetic signatures; important questions remain open. Therefore, studies in this field will provide new insights into PD pathologic processes, and consequently provide novel preventive and therapeutic intervention strategies.

Concluding Remarks and Perspectives
===================================

Currently, there is a plethora of methods used for measuring DNA methylation ([@B74]). To date the "gold standard" for the quantification of DNA methylation is still considered to be bisulfite sequencing. Nowadays this method is often used for genome-wide studies in combination with next-generation sequencing. However, the generation of bisulfite-converted DNA, and its subsequent use has often been described as technically challenging. Additionally, bisulfite conversion can lead to DNA fragmentation and can make amplification of long DNA regions difficult while resulting in chimeric products ([@B74]). An easier method is needed that does not require bisulfite conversion, for example, an endonuclease digestion-based assay (historically the first technique utilized for studying DNA methylation), which can be applied at gene-specific *loci*, but is also compatible with whole genome methylation profiling. Determining a standardized method for quantifying DNA methylation at the same genomic regions of reported PD-associated genes would be ideal for clinical research. Another issue is finding a method that can efficiently detect 5hmC and distinguish it from 5mC, not only on a genome-wide level, but also at bp resolution. Techniques applied to analyze DNA methylation changes associated with PD have mostly not discriminated between 5mC and 5hmC. Particularly in the brain, it will be of great interest to unravel whether the latter DNA methylation mark exhibits disease-specific patterns that could serve as biomarkers. A recent study found an approximate two-fold increase of global DNA hydroxymethylation in the cerebellum of PD patients ([@B125]). As this analysis lacks information about where these changes take place in the genome, further experiments will need to shed light on the cause, and examine whether elevated 5hmC levels contribute to PD onset or progression or PD is the reason for the aberrant hydroxymethylation. Approaches that can specifically detect 5hmC have been described, e.g., antibody-based techniques or oxidative bisulfite sequencing ([@B10]; [@B119]). These efforts make it likely that methods that discriminate between 5mC and 5hmC will be on hand in the future.

For now, more epigenetic studies are required, particularly ones conducted in different populations, to expand the currently available database of DNA methylation in PD-associated genes. Importantly, a more accurate consensus needs to be reached on the benefit of peripheral blood samples versus brain samples. For the DNA methylation status of a specific gene promoter, such as *SNCA* or other PD-associated genes to be authenticated as a reliable biomarker of PD status, a significant number of studies reporting consistent results will be needed. In this context, careful analysis of Levodopa treatment effects on *SNCA* DNA methylation offers the prospect that in the not-so-distant future a reliable DNA methylation biomarker in PD with high sensitivity and specificity will be available ([@B112]). With the growing interest in research on the interdependency between nutrition and epigenetics, in the future we will get a better understanding of what effects nutritional factors have on DNA methylation and what their involvement is in diseases like PD.

Epigenetic modifications may prove to be the missing link between environmental risk factors and the development of PD. Epigenetic variances between individuals could help us to explain the striking clinical differences observed in the age of onset and progression of sporadic PD, and may open the way for rational therapeutic intervention targeting DNA methylation modifications associated with this disorder.
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